MicroRNA-106b serves as a prognostic biomarker and is associated with cell proliferation, migration, and invasion in osteosarcoma

• Published in: Experimental and therapeutic medicine Vol. 18; no. 3; pp. 3342 - 3348
• Main Authors: Xu, Ke, Xiong, Wenhua, Zhao, Shoujun, Wang, Bin
• Format: Journal Article
• Language: English
• Published: Greece Spandidos Publications 01.09.2019; Spandidos Publications UK Ltd; D.A. Spandidos
• Subjects: Analysis; Biomarkers; Bone cancer; Cancer; Cancer metastasis; Cancer therapies; Cell adhesion & migration; Cell cycle; Cell growth; Committees; Development and progression; Gastric cancer; Health aspects; Males; Medical prognosis; Metastasis; MicroRNA; MicroRNAs; Novels; Oncology; Osteosarcoma; Polymerase chain reaction; Prognosis; Sarcoma; Scientific equipment industry; Studies; Surgery; Survival analysis; Tumors; United States; China; migration; invasion; proliferation; microRNA-106b; prognosis; osteosarcoma
• ISSN: 1792-1074; 1792-0981; 1792-1082
• DOI: 10.3892/ol.2019.10666

MicroRNAs (miRNAs) have been demonstrated to be involved in tumor progression of various human malignancies. The purpose of this study was to investigate the expression patterns and prognostic value of microRNA-106b (miR-106b) in osteosarcoma (OS) and to examine its functional role in OS progression. Reverse transcription-quantitative PCR (RT-qPCR) was used to estimate the expression of miR-106b in OS tissues and cells. The prognostic value of miR-106b in OS was evaluated by plotting Kaplan-Meier survival curves and performing Cox analyses. Cell experiments were carried out to examine the effects of miR-106b on OS cell proliferation, migration, and invasion. The expression of miR-106b was elevated in both OS tissues and cells compared with the expression in normal control tissues and cells (P<0.001). miR-106b expression was associated with metastasis (P=0.028) and Tumor-Node-Metastasis stage (P=0.017). Patients with high miR-106b expression levels had a poorer overall survival rate compared with those with low miR-106b expression levels (log-rank P=0.001). Multivariate Cox analyses indicated that miR-106b expression was an independent prognostic factor for patients with OS (hazard ratio=2.769; 95% confidence interval=1.369-5.599; P=0.005). The results of cell experiments implied that the upregulation of miR-106b could promote OS cell proliferation, migration and invasion, whereas the downregulation of miR-106b could suppress these functions (P<0.05). Taken together, this study's results indicated that the overexpression of miR-106b is associated with a poor prognosis for patients with OS and that overexpression promotes OS cell proliferation, migration, and invasion. This study may provide a novel prognostic biomarker and a candidate therapeutic target for OS treatment.